GlassScriptPhysician profile
Ramzy Medaa
NPI 1689981375
$2,377.65
in general payments reported to CMS, 2019-2025
22 companies · $24.05 in 2025
The $24.05 reported for 2025 was less than what a typical Neurology With Special Qualifications In Child Neurology provider received nationally (typical 2025 total: $275).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $866 · 2020: $126 · 2021: $490 · 2022: $324 · 2023: $210 · 2024: $338 · 2025: $24.05.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $571.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $571.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $400.61 | 2019-2024 | |
| Neurelis, INC. | $355.72 | 2020-2024 | Valtoco |
| Sunovion Pharmaceuticals INC. | $229.76 | 2019-2021 | |
| Eisai INC. | $207.65 | 2019 | |
| Ucb, INC. | $189.28 | 2020-2024 | Nayzilam |
| Supernus Pharmaceuticals, INC. | $125.58 | 2020-2022 | |
| Jazz Pharmaceuticals INC. | $125.00 | 2019 | |
| Sumitomo Pharma America, INC. | $124.99 | 2023 | Aptiom |
| Csl Behring | $108.73 | 2020-2022 | |
| Pfizer INC. | $101.11 | 2019 | |
| Allergan, INC. | $85.66 | 2019 | |
| Biogen, INC. | $75.30 | 2021 | |
| Corium, LLC | $46.47 | 2022 | |
| Sobi, INC | $39.44 | 2021-2022 | |
| Zogenix INC. | $24.13 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mauna Kea Technologies, INC. | $24.05 | 2025 | |
| Aprecia Pharmaceuticals, LLC | $22.47 | 2023 | Spritam |
| Takeda Pharmaceuticals U.S.A., INC. | $21.00 | 2020 | |
| Livanova USA, INC. | $20.80 | 2020 | |
| Alexion Pharmaceuticals, INC. | $18.76 | 2019 | |
| Tris Pharma INC | $17.95 | 2023 | Dyanavel Xr |
| Biomarin Pharmaceutical INC. | $13.19 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ramzy Medaa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.